Brian D. Lichty
McMaster University
Publications 94
#1Jonathan PolH-Index: 16
#2Byram W. Bridle (U of G: University of Guelph)H-Index: 16
Last.Brian D. Lichty (McMaster University)H-Index: 37
view all 3 authors...
#1Aj Robert McGrayH-Index: 4
#2Ruea-Yea HuangH-Index: 2
Last.Kunle OdunsiH-Index: 51
view all 12 authors...
Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy. As such, identifying strategies to bolster anti-tumor immunity and limit immune suppression, while recognizing diverse patterns of tumor response to immunotherapy is critical to selecting treatment combinations that lead to durable therapeutic benefit. Using a pre-clinical mouse model, we evaluated a heterologous prime/boost vaccine in co...
#1Scott R. WalshH-Index: 3
#2Boris SimovicH-Index: 1
Last.Yonghong WanH-Index: 37
view all 10 authors...
#1Karina Kawka (McMaster University)H-Index: 1
#2Pedram Madadkar (McMaster University)H-Index: 6
Last.David R. Latulippe (McMaster University)H-Index: 11
view all 8 authors...
Abstract Viruses are an emerging class of biotherapeutics with the potential to treat cancer, genetic, cardiovascular and other diseases. Their commercial success depends on cost-effective purification processes. Membrane chromatography processes offer great potential for virus purification, however conventional devices are known to suffer from issues related to resolution and sample dilution. Laterally-fed membrane chromatography (LFMC) overcomes these issues by minimizing the dead-volume and e...
#1Steven P. Toniolo (McMaster University)H-Index: 1
#2Sam Afkhami (McMaster University)H-Index: 8
Last.Michael Thompson (McMaster University)H-Index: 24
view all 9 authors...
Abstract Two enveloped viral vectors, vesicular stomatitis virus and influenza virus, and a non-enveloped viral vector, human adenovirus type 5, were encapsulated by spray drying to enhance thermal stability. Results with these candidates led to the hypothesis that stability performance of chosen excipients may be less virus-specific, as previously postulated in the literature, and more differentiated based on whether the virus has a lipid envelope. Spray dried samples were characterized for the...
1 CitationsSource
#1Jonathan Pol (McMaster University)H-Index: 16
#2Sergio A. Acuna (UHN: University Health Network)H-Index: 12
Last.J. Andrea McCart (UHN: University Health Network)H-Index: 18
view all 27 authors...
ABSTRACTMultiple immunotherapeutics have been approved for cancer patients, however advanced solid tumors are frequently refractory to treatment. We evaluated the safety and immunogenicity of a vaccination approach with multimodal oncolytic potential in non-human primates (NHP) (Macaca fascicularis). Primates received a replication-deficient adenoviral prime, boosted by the oncolytic Maraba MG1 rhabdovirus. Both vectors expressed the human MAGE-A3. No severe adverse events were observed. Boostin...
8 CitationsSource
#1Jonathan PolH-Index: 16
Last.Brian D. LichtyH-Index: 37
view all 14 authors...
8 CitationsSource
#1Matthew J. Atherton (McMaster University)H-Index: 6
#2Kyle B. StephensonH-Index: 12
Last.Brian D. Lichty (McMaster University)H-Index: 37
view all 19 authors...
ABSTRACTProstate cancer (PCa) was estimated to have the second highest global incidence rate for male non-skin tumors and is the fifth most deadly in men thus mandating the need for novel treatment options. MG1-Maraba is a potent and versatile oncolytic virus capable of lethally infecting a variety of prostatic tumor cell lines alongside primary PCa biopsies and exerts direct oncolytic effects against large TRAMP-C2 tumors in vivo. An oncolytic immunotherapeutic strategy utilizing a priming vacc...
4 CitationsSource